D. E. Shaw & Co., Inc. Actinium Pharmaceuticals, Inc. Transaction History

D. E. Shaw & Co., Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$6.56 - $9.89 $192,450 - $290,142	29,337 New	29,337 $217,000
Q3 2023 Nov 14, 2023	SELL	$5.91 - $7.37 $63,544 - $79,242	-10,752 Reduced 37.39%	18,002 $106,000
Q2 2023 Aug 14, 2023	SELL	$7.15 - $9.39 $86,829 - $114,032	-12,144 Reduced 29.69%	28,754 $213,000
Q1 2023 May 15, 2023	SELL	$8.51 - $14.26 $2.01 Million - $3.37 Million	-236,222 Reduced 85.24%	40,898 $386,000
Q4 2022 Feb 14, 2023	BUY	$7.05 - $14.41 $1.69 Million - $3.45 Million	239,196 Added 630.72%	277,120 $2.95 Million
Q3 2022 Nov 14, 2022	BUY	$4.81 - $8.48 $99,085 - $174,688	20,600 Added 118.91%	37,924 $280,000
Q2 2022 Aug 15, 2022	SELL	$4.71 - $7.11 $26,898 - $40,605	-5,711 Reduced 24.79%	17,324 $83,000
Q1 2022 May 16, 2022	SELL	$4.57 - $6.4 $11,141 - $15,603	-2,438 Reduced 9.57%	23,035 $118,000
Q4 2021 Feb 14, 2022	SELL	$6.01 - $8.8 $15,902 - $23,284	-2,646 Reduced 9.41%	25,473 $153,000
Q3 2021 Nov 15, 2021	BUY	$5.76 - $9.67 $161,965 - $271,910	28,119 New	28,119 $249,000
Q1 2021 May 17, 2021	SELL	$7.62 - $9.79 $489,059 - $628,331	-64,181 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$7.8 - $12.64 $500,611 - $811,247	64,181 New	64,181 $501,000

8.38M

65.2K

21.7K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $30.2M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.